No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - JPMorgan lifted its price target on Marks & Spencer on Tuesday to 450p from 440p as it reiterated its 'overweight' rating, arguing that the turnaround is gaining traction.
The bank said M&S has a clear, quantifiable opportunity to close a meaningful portion of its online margin gap in Fashion, Home & Beauty (FH&B) as the Lichfield distribution centre ramps.
JPM said it had identified three tangible building blocks to around 400 basis points of FH&B online margin upside, leading it to lifts its FY29 group pre-tax profit forecast by 6%.
"This leaves us low single digit percentage ahead of Bloomberg consensus on group profit before tax, and 6%/ 5% higher on FH&B/ Food EBIT," the bank said. "We do not view this as the maximum margin improvement available, nor the only opportunity in the business - but we are comfortable embedding this upside given the tangible building blocks laid out in detail in this note.
"Indeed, our bull case scenario, also incorporating better order economics and sourcing benefits, would drive a further 7% upside to our PBT forecast, and would leave us double digit percentage ahead of consensus."
JPM also said the valuation remains undemanding, noting that M&S trades on 10.7x CY27 price-to-earnings, which is around 7% below its five-year pre-pandemic average, despite materially better turnaround visibility.
"We raise our Mar-28 multiples-based TP to 450p (from 440p), applying a circa 13x multiple (a 10% premium to the pre-pandemic average) to reflect our view that the turnaround is regaining traction," it said.
At 1452 BST, M&S shares were up 3.5% at 393.10p.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.